

International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

Volume 3, Issue 4, May 2023

# **QA & QC in Pharmaceutical Industry**

Mr. Harshad K. Pawar, Miss. Apeksha S. Jadhav, Miss. Shivani P. Kale, Miss. Swapnali T. Bhosale Nootan College of Pharmacy Kavathe Mahakal, Sangli, Maharashtra, India

**Abstract:** This chapter defines the quality control (QC) procedures and factors that are obligatory in the performance of analyses, and indicates the QC information that must be generated with the logical data. The factors of a quality assurance(QA)/QC program can be classified as operation and as functional. QA is a necessary part of data product, and it serves as a companion for the operation of the laboratory for product quality data. The responsibility of icing that the QA/QC measures are duly employed must be assigned to a knowledgeable person who isn't directly involved in the slice and analysis. liabilities of such an officer may range from periodic reviewing of the program to conducting system checkups and internal performance checkups on a routine and continuing base. Judges must be well- trained for both specialized and QA/QC liabilities.

Keywords: Quality Assurance, Quality Control, Warehousing, IPQC.

### I. INTRODUCTION

**Introduction to Quality Assurance and Quality Control:** The goal of quality assurance and quality control (QA/QC) is to identify and implement sampling and analytical methodologies which limit the introduction of error into analytical data. A high quality system may be a management system that describes the elements necessary to set up, implement, and assess the effectiveness of QA/QC activities. this system establishes many functions including: quality management policies and guidelines for the development of organization- and project-specific quality plans; Criteria and guidelines for assessing information quality; assessments to determine effectiveness of QA/QC implementation; The goal of satisfactory assurance and nice control (QA/quality controls) is to pick out and enforce sampling and analytic.

**Scope of QA&QC in pharmaceutical:-** The main objective of quality control in the Pharmaceutical industry is to test the drugs in their varied stages of production, medicine that they are ready to proceed to consecutive stage and unharness the manufacturing process in accordance with the rules and specifications required for consumption. Manufacturing Practice (CGMP) Regulations FDA ensures the quality of drug products by rigorously monitoring drug manufacturers' compliance with its Current good manufacturing observe (CGMP) laws. The CGMP regulations for drugs contain minimum necessities for the strategies, facilities, and controls utilized in manufacturing, processing, and packing of a drug product.

### ICH guidelines: Quality, safety, efficacy, multidisciplinary:-

• (QSEM): The ICH guidelines are covered below four headings below the word form QSEM - Quality, Safety, efficacy and Multidisciplinary.

(a) Quality guidelines: These guidelines cover the areas of quality of drug products such as impurity testing and stability studies and a flexible approach to quality on the basis of GMP risk management.(b) Safety guidelines: they help to detect potential risks such as Geno toxicity, carcinogenicity and nephrotoxicity.

(c) Efficacy guidelines: These guidelines provide guidance regarding designing, conducting, safety aspects and coverage of clinical for pharmaceutical product

**d)** Multidisciplinary guidelines: Topics in the pharmaceutical field that do not match into any of the on top of categories square measure covered under this area. This guideline conjointly includes details of (Med DRA), CTD and standards such as Electronic Standards for the Transfer of regulative data (ESTRI)

**Good Warehousing**: Good warehousing practices (GWP) suggests that storing supplies so that products are continually available, accessible, and in physical fitness. Unhealthy warehousing cause damages resulting in losses. Pharmaceutical warehousing, therefore, is much over the straightforward storage of product. It's an operation that preserves the integrity of medication. According to cGMP drugs must be hold on to prevent contamination, and be positioned to allow for inspection and cleaning of the realm. Each lot of drug product must be identified with a distinctive (and

Copyright to IJARSCT www.ijarsct.co.in DOI: 10.48175/IJARSCT-9853



141



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

### Volume 3, Issue 4, May 2023

traceable) code, and the lot's status must be identified (approved, quarantined, and rejected). Written procedures must describe the distribution process for each drug.

Analysis of Raw material:- Raw materials are principally the chemical constituents of a process. They are starting material, which is used in production of final product. The procedures in place to test the suppliers of raw materials (check-ups, supplier history, character). Raw materials with abnormally high microbial impurity may have to be subordinated to a sterilization procedure like heat treatment, radiation or crystallization from bactericidal detergent like alcohol. Following rudiments need to be considered when establishing storages operation Cleanliness, bottoms, lighting & bribes. Raw materials testing ensures that the raw materials used in pharmaceutical products are suitable for their use. Analysis of Packaging material and finished product:- Packaging is a process by which the medicinal products are suitably packed so that they should retain their remedial effectiveness from the time of packaging till they're consumed. Pharmaceutical packaging is the means of furnishing protection, donation, identification, information and convenience to encourage compliance with a course of remedy. Composition of package involves Container, Closure, Carton or external, Box, etc. Finished products are products which are in the marketable pack. Each batch of the finished product should be tested as per sop and also release the product for trade or distribution. There are different tests for determination of quality, integrity and compatibility of packaging materials. Containers are tested by numerous styles of which generally used test for glass are Crushed glass test, Whole- Container test, Chemical resistance of test, Water Attack Test etc.

Definition of IPQC: IPQC stands for IN PROCESS QUALITY CONTROL. These are checks that are carried out before the manufacturing process is completed. The function of in- process controls is covering and if necessary adaptation of the manufacturing process in order to misbehave with the specifications.

**Records:**- This Final league in the Quality Documentation System. All the data, information, records, forms, etc. are archived. Quality records are the objective substantiation to prove that the Quality System is being executed per procedure. Quality Records also describe how the quality of the end product was vindicated to have met the specifications and also meet the client's requirements & prospects. Records include Non-Conformance examinations, CAPA's, Inspection Results, Supplier Attestation, Estimation Results, and Conservation Records.

Standard Operating Procedures (SOP):- SOPs can be defined as written documents specifying the procedure that must be followed to carry out operation. One of the purposes of SOPs is to reduce the preface of crimes and variation in the operation. The other purpose of sops is of literal perspective i.e. how operation was carried out. An SOP is a written document or instruction detailing all way and conditioning of a process or procedure. These should be carried out without any divagation or revision to guarantee the anticipated outgrowth.

Master Batch Record:- The functionary written instructions or form for the manufacturing of each particular product part number using a specific manufacturing process. The Master Batch Record should claim the following information, for example Identification of product name.

Element list.

Statement of theoretical yield at each step in the manufacturing process.

Anticipated yield of the finished product.

Specific instructions for each state in the manufacturing process.

Slice and testing procedures.

Instructions for homemade operations.

Batch Manufacturing Record: - Batch manufacturing record shall be basically grounded on the master formula record and shall include:

Name of the product

Batch number

Date of inception & completion of significant intermediate stage.

Name of the person responsible for each stage of product

Original of drivers who carried out significant processes and original of persons who checked, wherever applicable.

Drug Master File Submission:- Drug Master File Submission (DMF submission) isn't obligatory for the US FDA as U.S. DMFs are neither approved nor disapproved. Still, to maintain the confidentiality and to relate in multiple DMFs, manufacturers DMF holders practice maintaining independent DMF cessions for the drug substances excipients

Copyright to IJARSCT

DOI: 10.48175/IJARSCT-9853





142



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

### Volume 3, Issue 4, May 2023

packaging accoutrements. To be biddable with the general medicine stoner Fee Act (GDUFA) II and Initial Completeness Assessment (ICA) conditions of the US FDA, the DMF holders must insure that their DMF is biddable with the FDA prerequisites. It's critical to admit the acceptance to the DMF/ blessing of the operations pertaining to the DMF, which will enable the DMF holder to give access through a Letter of Access (LoA) to multiple operations similar as IND/ NDA/ ANDA/ DMF.

**Regulated Market:-** These countries have well- defined procedures for marketing and distribution of medicinal both for mortal and veterinary use. MAHs should file operations to market their medicines with all the probative and required data. E.g. Major big countries with specific authorities monitoring bodies to look after health of its citizens US, JAPAN, AUSTRALIA, CANADA, INDIA ,Etc. Regulated pharma markets bear submission of dossier in CTD format which has to give clinical trial and bioequivalence studies.

**Non-regulated market in pharmaceutical industry:-** Non-regulated Small to veritably countries which don't have any specific authorities which controls the force of drug. One can consider recently formed countries, small population countries and under developed countries. AFRICAN countries, Asian countries being said since these countries don't have specific covering authorities, they depend on other regulated countries. If particular product is retailed in any of the regulated countries.

**Drug Discovery:-** Drug discovery can be described as the process of identifying potential therapeutic compounds. A major goal of drug discovery campaigns is to identify new molecular entities that can help treat diseases with unmet medical needs. There are no definitively useful treatments for these diseases, and they can be real and life-threatening.

**Drug Development:-**Drug development is the process of bringing new drug molecules into the clinic. At a high level, this includes all steps from basic research to find suitable molecular targets to supporting drug launches. In a narrow sense, development refers only to the clinical part of this process, while discovery is used to describe the non-clinical research component. This topic is rich in technical terms that different companies and individuals use in different ways.

**Investigational new drug application (IND):-** An IND is technically a vehicle for sponsors to obtain this waiver from the FDA. A sponsor's primary goal in early preclinical development of a new drug is whether the product is reasonably safe for first human use and whether the compound has the pharmacological activity to justify commercial development. It is the decision to demonstrate whether the product has been identified as a suitable candidate for further development, and the sponsor should consider whether the product is in early entry into limited clinical trials. Collects the data necessary to determine that does not expose humans to undue risk; and information gathering.

Abbreviated New Drug Application (ANDA):- Once approved, the applicant will be able to manufacture and market generic drugs to provide a safe, effective and inexpensive alternative to the associated branded drug. A generic medicinal product is a medicinal product that is comparable to the innovative medicinal product in terms of dosage form, strength, and route of administration, quality, performance characteristics and intended use. All approved products, both branded and generic, are on the FDA's Regulatory Review of Drug and Therapeutic Equivalence (Orange Book).

**Calibration:** Calibration is the process of configuring an instrument to give a result for a sample within a respectable range. Barring or minimizing factors that beget inaccurate measures is an abecedarian aspect of instrumentation design.

**Qualification:** The act of proving and establishing that outfit or ancillary systems are duly installed, work rightly, and misbehave with specified conditions. The process used to demonstrate the capability to fulfill specified conditions.

**Validation:** Validation is a proved program that provides high degree of assurance that a specific process, outfit, system or system constantly produces a result meeting pre-determined acceptance criteria.

**Quality By Design (Qbd)**-:Quality by Design (QbD), a concept introduced byDr. JosephM. Juran, emphasizes the design of quality into product. Quality- by- Design is defined as" a organized approach to pharmaceutical development with predefined aims". This approach emphasizes product and process control, based on sound science and . A high quality drug product, as defined by Janet Woodcock (Director for the Centre for medicament Evaluation and examine), is a product free of contaminant which can ever deliver the clinical performance and medicinal plunder as indicated in the tag. It was honoured that the quality of product does not upgrade with increased testing. Following equation indicates the factors affecting quality.

Copyright to IJARSCT www.ijarsct.co.in DOI: 10.48175/IJARSCT-9853



143



International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

### Volume 3, Issue 4, May 2023

### Audit:

International organization for standardization (ISO) defines the audits as" Systematic, independent and documented process for obtaining audit evidence and evaluating them objectively to determine the degree to which the verification criteria are met".

### Intellectual property:

**Scope of intellectual Property:** Intellectual property rights (IPR) refers to the legal rights given to the inventor or creator to protect his invention or creation for a certain period of time. These legal rights confer an exclusive right to the inventor/creator or his assignee to fully utilize his invention/creation for a given period of time.

**Trademark**: Trademarks already existed in the ancient world. The Indian crafts men used to engrave their signature on their jeweler or inventive creation around 3000 years ago. With industrialization the trademark become key factor in modern world of international trade. A trade mark is a distinctive sign or logo that denotes about the particular item is produced or provided by a specific person or industry or enterprise. Similar to trademark, service mark distinguish service providing enterprises with their competitors.

**Patent**: Patent is an intellectual property right granted to inventor by concerned government office for his novel technical invention. The term invention means answer of any problem in terms of development of a product or a process. Among the different types of IPR, patents are considered the most valuable and rightly.

### REFERENCES

- A Text book of Pharmaceutical Quality Assurance by the author Anusuya R.Kashi, Bindu Sukumaran, And Veena P. Nirali Prakashan. Page No.3.1-3.8
- [2]. Pee Vee book of Pharmaceutical Quality Assurance by Dr. Swarnali Das Paul, Mrs. Gunjan Jeswani, Page no: 255 – 275
- [3]. FDA. 1998. Human drug cGMP notes, vol. 6, no. 4. Rockville, Md., USA: Food and Drug Administration, Center for Drug Evaluation and Research.
- [4]. Gavlick, W. K., L. A. Ohlemeier, H. J. Kaiser. Pharmaceutical Technology.
- [5]. FDA. 1993. Guide to inspections of validation of cleaning processes. Rockville, Md., USA: Food and Drug Administration, Office of Regulatory Affairs.
- [6]. LeBlanc, D. A. 1998. Pharmaceutical Technology.
- [7]. ICH. 1995. Guideline for industry: Text on validation of analytical procedures.
- [8]. ICH. 1997. Guideline on the validation of analytical procedures: Methodology...
- [9]. FDA. 1998. Human drug cGMP notes, vol. 6, no. 4. Rockville, Md., USA: Food and Drug
- [10]. Administration, Center for Drug Evaluation and Research.
- [11]. Gavlick, W. K., L. A. Ohlemeier, H. J. Kaiser. Pharmaceutical Technology 19 (3):1 36-14 4.
- [12]. FDA. 1993. Guide to inspections of validation of cleaning processes. Rockville, Md., USA:
- [13]. Food and Drug Administration, Office of Regulatory Affairs.
- [14]. LeBlanc, D. A. 1998. Pharmaceutical Technology 22 (10): 136-148.
- [15]. ICH. 1995. Guideline for industry: Text on validation of analytical procedures. Federal Register 60: 1 1260.
- [16]. ICH. 1997. Guideline on the validation of analytical procedures: Methodology. Federal Register 62:27463.
- [17]. USP. 1995. United States Pharmacopeia, 23rd ed. <1225> Validation of compendial methods. Rockville, Md., USA: United States Pharmacopeial Convention, pp. 1982-1984.
- [18]. Kirsch, R. B. 1998. Validation of analytical methods used in pharmaceutical cleaning assessment and validation. In 1998
- [19]. Kaiser, H. J., and J. F. Tirey. 1999. Measurement of organic and inorganic residues on surfaces. Paper Presented at Pittcon '99, 7-12 March in Orlando, Fla
- [20]. Smith, J. 1993. Pharmaceutical Technology 17 (6):B B-98.
- [21]. Sinha B, Joshi H & Ghosh P K, Challenges in creation and management of knowledge capital in technical educational institutions, Journal of Intellectual Property Rights, 14 (2009) 340-345.
- [22]. Nair M D, TRIPS, WTO and IPR World Patents, Journal of Intellectual Property Rights, 15 (2010) 151-53.





International Journal of Advanced Research in Science, Communication and Technology (IJARSCT)

International Open-Access, Double-Blind, Peer-Reviewed, Refereed, Multidisciplinary Online Journal

### Volume 3, Issue 4, May 2023

- [23]. Mishra N, Registration of non-traditional trademarks, Journal of Intellectual Property Rights, 13 (2008) 43-50
- [24]. Verma S K, Financing of intellectual property: Developing countries' context, Journal of Intellectual Property Rights, 11 (2006) 22-32.
- [25]. Nair M D, GATT, TRIPS, WTO and CBD-relevance to agriculture, Journal of Intellectual Property Rights, 16 (2011)176-182.
- [26]. Venkataraman K & Latha S S, Intellectual property rights, traditional knowledge and biodiversity of India, Journal of Intellectual Property Rights, 13 (2008) 326-335.

